The stimulatory loop formed by GHRH and its receptors can be blocked by GHRH antagonists, which exhibit antitumor functions across various cancer types, by directly inhibiting SV1 signaling or blocking tumor-derived insulin-like growth factor 1 (IGF1) and IGF2. Here, IGF1 is linked to cancer.